Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Hypertension. 2020 May 18;76(1):226–235. doi: 10.1161/HYPERTENSIONAHA.119.14315

Figure 3.

Figure 3.

Passive structural measurements of LMAs from Wistar rats, SHRs treated with hydralazine, captopril or vehicle. A, Changes in passive inner diameter in response to increased intravascular pressure. There was a significant pressure effect [F(1, 213)=500.10, P<0.01], but no significance in pressure by group interaction or group effect [F(3, 213)=0.39, F(3, 27)=2.87; P>0.05]. *P<0.05 vs. Wistar and SHR-Hydral rats by pairwise group comparisons. B, Changes in passive outer diameter in response to increased intravascular pressure. There was a significant pressure effect [F(1, 213)=289.87, P<0.01], but no significance in pressure by group interaction or group effect [F(3, 213)=0.96, F(3, 27)=2.82; P>0.05]. *P<0.05 vs. SHR-Hydral rats by pairwise group comparisons. C, Changes in wall thickness in response to increased intravascular pressure. There was a significant pressure effect [F(1, 213)=115.50, P<0.01], but no significance in group by pressure interaction or group effect [F(3, 213)=1.68, F(3, 27)=0.90, P>0.05]. D, percent distensibility in response to increased intravascular pressure. There was a significant pressure effect [F(1, 213)=534.31, P<0.01], but no significance in pressure by group interaction or group effect [F(3, 213)=0.55, F(3, 27)=0.03; P>0.05]. Wistar: n=8; SHR-Hydral: n=7; SHR-Capto: n=8; SHR-Veh: n=8. Data were analyzed by mixed model repeated measures ANOVA.